Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients
M Pitzalis, ML Idda, V Lodde, A Loizedda… - Frontiers in …, 2021 - frontiersin.org
Objectives Vaccination against COVID-19 is highly recommended to patients affected by
multiple sclerosis (MS); however, the impact of MS disease-modifying therapies (DMTs) on
the immune response following vaccination has been only partially investigated. Here, we
aimed to elucidate the effect of DMTs on the humoral immune response to mRNA-based anti-
SARS-CoV-2 vaccines in MS patients. Methods We obtained sera from 912 Sardinian MS
patients and 63 healthy controls 30 days after the second dose of BNT162b2 vaccine and …
multiple sclerosis (MS); however, the impact of MS disease-modifying therapies (DMTs) on
the immune response following vaccination has been only partially investigated. Here, we
aimed to elucidate the effect of DMTs on the humoral immune response to mRNA-based anti-
SARS-CoV-2 vaccines in MS patients. Methods We obtained sera from 912 Sardinian MS
patients and 63 healthy controls 30 days after the second dose of BNT162b2 vaccine and …
以上显示的是最相近的搜索结果。 查看全部搜索结果